Q32 Bio Inc.
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company's website is www.ayalapharm.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Q32 Bio Inc. does
In the company’s own words
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company's website is www.ayalapharm.com.
The company's most advanced product candidate is bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody designed to block signaling mediated by interleukin-7 and thymic stromal lymphopoietin. Bempikibart has completed two Phase 2a clinical trials and is currently being evaluated for the treatment of alopecia areata in the ongoing SIGNAL-AA Phase 2a Part B clinical trial, with enrollment completed at 33 patients. The company expects to report 36-week topline data from this trial in mid-2026. In April 2025, the FDA granted Fast Track designation to bempikibart for alopecia areata treatment, facilitating expedited development and review. Across all clinical trials to date, bempikibart has been dosed in over 150 participants and has demonstrated a favorable safety and tolerability profile with no Grade 3 or higher related adverse events.
Beyond bempikibart, Ayala Pharmaceuticals maintains a proprietary tissue-targeted complement inhibitor platform. In November 2025, the company sold substantially all assets related to ADX-097, a Phase 2 complement inhibitor candidate, to Akebia Therapeutics, Inc. for an upfront payment of seven million dollars with potential milestone and royalty payments. The company retains rights to ADX-096 and other early-stage assets from its complement platform while evaluating strategic options for these programs.
The company was founded on discoveries from renowned immunology researchers and has received support from leading biotechnology investors including OrbiMed, Atlas Venture, Abingworth, and Bristol-Myers Squibb. Ayala Pharmaceuticals has assembled a team of industry experts with extensive experience in advancing drug candidates for autoimmune and inflammatory diseases. The company has no products approved for commercial sale and has not generated product revenue to date.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1661998
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Q32 Bio Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Q32 Bio Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Q32 Bio Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Q32 Bio Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Q32 Bio Inc.'s last four quarterly filings that the numbers alone won't show?”